This video shows how to track the metabolites of metoprolol in GastroPlus 9.5.
Model-informed drug development for malaria therapeutics
Malaria is a critical public health problem resulting in substantial morbidity and mortality, particularly in developing countries. Owing to the development of resistance toward current therapies, novel approaches to accelerate...
Simulations Plus Sets Date for 1st Quarter 2018 Earnings Release and Conference Call
Conference Call to be on Tuesday, January 9, 2018, at 4:15 PM ET
Developing a mechanistic absorption model to predict the pharmacokinetics of immediate-release weak base drugs with a long Tmax by incorporating lysosomal trapping.
The objectives of this study were 1) to develop and verify mechanistic absorption models to predict the pharmacokinetics (PK) of two immediate-release weak base drug (WBD) products (Drug X and Drug Y) with a...
In Vitro Dissolution Methodology And Estimated Consequences Of Biowaiver Extension For Immediate Release Solid Oral Dosage Forms With Metformin Hydrochloride
The in vitro dissolution methodologies are frequently used as quality control tools for the assessment of solid oral dosage forms.
Every Jack has His Jill: Finding a Target for Your Combinatorial Library
Pharmaceutical companies regularly run campaigns to evolve their proprietary chemical libraries which are among their most valuable assets.
Physiologically Based Oral Absorption Modelling to Study Gut-Level Drug Interactions
Physiologically based oral absorption models are in silico tools primarily used to guide formulation development and project the clinical performance of formulation variants.
The Combination of GIS and Biphasic to Better Predict In Vivo Dissolution of BCS Class IIb Drugs, Ketoconazole and Raloxifene
The formulation developments and the in vivo assessment of Biopharmaceutical Classification System (BCS) class II drugs are challenging due to their low solubility and high permeability in the...
Synaptophysin expression on circulating tumor cells in patients with castration resistant prostate cancer undergoing treatment with abiraterone acetate or enzalutamide
Background: With the advent of secondary androgen receptor (AR)-targeted therapies in metastatic castration resistant prostate cancer (PC), nonadenocarcinoma PCs are...
Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC)
Background: Two androgen receptor (AR)-targeted therapies, enzalutamide and abiraterone acetate plus prednisone (abiraterone), have been approved for the treatment...
Tracking Metabolites in GastroPlus®
This video shows how to track the N-debutyl metabolite of dronedarone in GastroPlus.
Wildfire Forces Cancelation of LD Micro Conference
Presentations Canceled for Celsius Holdings, Inc., GSI Technology, Inc., PCM, Inc., Simulations-Plus, ADOMANI, Inc., HUTN, Inc., NanoVibronix, Inc. and WidePoint Corp.
IVIVC using in silico and PBPK methods for inhaled drug product development
The physiologically based model of the lung included in GastroPlus™ was used to simulate the absorption, distribution, and pharmacokinetics of two APIs from an inhaled combination product.
2017 White Paper: rise of hybrid LBA/LCMS immunogenicity assays (Part 2: hybrid LBA/LCMS biotherapeutics, biomarkers & immunogenicity assays and regulatory agencies’ inputs)
The 2017 11th Workshop on Recent Issues in Bioanalysis (11th WRIB) took place in Los Angeles/Universal City, California on 3-7 April 2017 with participation of close to 750 professionals from pharmaceutical/biopharmaceutical companies, biotechnology companies, contract research organizations and regulatory agencies worldwide.
Refining Liver Safety Risk Assessment: Application of Mechanistic Modeling and Serum Biomarkers to Cimaglermin Alfa (GGF2) Clinical Trials
Cimaglermin alfa (GGF2) is a recombinant human protein growth factor in development for heart failure.
Software based approaches for drug designing and development: A systematic review on commonly used software and its applications.
Drug discovery include drug designing and development, is a multifarious and expensive endeavor, where least number of drugs that pass the clinical trials makes it to market.
Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer
Background The signaling protein p38 mitogen-activated protein kinase (MAPK) regulates the tumor cell microenvironment, modulating cell survival, migration, and invasion.
Modeling of prolactin response following dopamine D2 receptor antagonists in rats: can it be translated to clinical dosing?
Prolactin release is a side effect of antipsychotic therapy with dopamine antagonists, observed in rats as well as humans.
Mechanistic In Vitro Dissolution PBPK Models to Drive Drug Development
In this webinar, DDDPlus™, an in vitro simulation platform focused on providing predictive dissolution & precipitation tools for formulation development, will be presented in conjunction with GastroPlus™ to...
Simulations Plus Releases ADMET Predictor™ Version 8.5
New HTPK Simulation Module allows chemists to screen compound libraries using novel approach